secwatch.observer — SEC 8-K summary
======================================

Issuer:     NIKA PHARMACEUTICALS, INC (NIKA)
CIK:        0001145604
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001826466-24-000020
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nika Pharmaceuticals completes merger with Nika BioTechnology; increases preferred authorized shares
--------------------------------------------------------------------------------

- Merger effective March 1, 2024; Nika BioTech shareholders receive 1 NKPH share per NIKA share.
- Controlling shareholder Dimitar Slavchev Savov owns ~69% of merged entity's common and 100% of Preferred A.
- Articles amended to increase authorized Preferred A shares from 10M to 15M, filed March 4, 2024.
- Both companies had same board and officers; management unchanged post-merger.
- Shareholders approved the merger on February 12, 2024, and the transaction closed as planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1145604/000182646624000020/0001826466-24-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1145604/000182646624000020/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001826466-24-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer